Antonio Sergio Navarro Fernandez
Directeur/Membre du Conseil chez Universal Diagnostics SA
Profil
Antonio Sergio Navarro Fernandez has a current job as a Director at Universal Diagnostics SA.
Postes actifs de Antonio Sergio Navarro Fernandez
| Sociétés | Poste | Début |
|---|---|---|
Universal Diagnostics SA
 Universal Diagnostics SA Electronic Equipment/InstrumentsElectronic Technology Universal Diagnostics SL is a bioinformatics and multi-omics company based in Seville, Spain. The Spanish company's mission is to transform cancer into a curable disease by developing blood tests that detect cancer in its earliest stages. The company's first single-draw blood test, Signal-C, accurately detects colorectal cancer with a sensitivity rate of 92%% and specificity rate of 97%%, with extraordinary accuracy for earlier stages (89%%/97%%). The company is developing Signal-X™, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity. With its multi-omics + computational biology + machine learning approach, the company is cracking the code to "true" early cancer detection, having identified the specific cfdna sequence regions that capture cancer's earliest signal with +90%% accuracy. The company was founded by Marko Bitenc and Juan Martínez Barea, with Juan Martínez Barea serving as the CEO since incorporation. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Universal Diagnostics SA
Universal Diagnostics SA Electronic Equipment/InstrumentsElectronic Technology Universal Diagnostics SL is a bioinformatics and multi-omics company based in Seville, Spain. The Spanish company's mission is to transform cancer into a curable disease by developing blood tests that detect cancer in its earliest stages. The company's first single-draw blood test, Signal-C, accurately detects colorectal cancer with a sensitivity rate of 92%% and specificity rate of 97%%, with extraordinary accuracy for earlier stages (89%%/97%%). The company is developing Signal-X™, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity. With its multi-omics + computational biology + machine learning approach, the company is cracking the code to "true" early cancer detection, having identified the specific cfdna sequence regions that capture cancer's earliest signal with +90%% accuracy. The company was founded by Marko Bitenc and Juan Martínez Barea, with Juan Martínez Barea serving as the CEO since incorporation. | Electronic Technology |
